19. Psychotropic Drugs

Tina Hinton

Department of Pharmacology, School of Medical Sciences, The University of Sydney, NSW, 2006, Australia

Phone: +61 2 9351 6208; Fax: +61 2 9351 3868; Email: tina.hinton@sydney.edu.au

Key words: depression, antidepressants, neurochemistry, tricyclic antidepressants, imipramine, monoamine oxidase inhibitors, phenelzine, moclobemide serotonin reuptake inhibitors, fluoxetine, combined serotonin and noradrenaline reuptake inhibitors, venlafaxine, psychosis, schizophrenia, typical antipsychotics, chlorpromazine, haloperidol, atypical antipsychotics, clozapine, olanzapine, fear, anxiety, benzodiazepine, diazepam, midazolam, temazepam, buspirone

Contents

19.1 Depression and Antidepressants

            19.1.1 Depression

19.1.2 Neurochemistry of Depression and the Monoamine Theory

19.1.3 Antidepressant Indications and Drug Classes

19.1.4 General Considerations with the use of Antidepressants

19.1.5 Tricyclic Antidepressants

19.1.6 Monoamine Oxidase Inhibitors

19.1.7 Selective Serotonin Reuptake Inhibitors

19.1.8 Combined Serotonin and Noradrenaline Reuptake Inhibitors

19.1.9 Long Term Adaptive Changes with Antidepressants

19.2 Psychosis, Schizophrenia, and Antipsychotics

            19.2.1 Psychosis and Schizophrenia

19.2.2 Neurochemistry of Psychosis and the Dopamine Theory

19.2.3 Antipsychotic Drug Indications and Drug Classes

19.2.4 Antipsychotic Mechanisms of Action

19.2.5 Typical Antipsychotics (First Generation)

19.2.6 Atypical Antipsychotics (Second Generation)

19.3 Anxiety and Anxiolytics

            19.3.1 Fear, Anxiety and Anxiety Disorders

19.3.2 Neurochemistry of Anxiety

19.3.3 Anxiolytic Drug Indications and Drug Classes

19.3.4 Benzodiazepines

19.3.5 Antidepressants

19.3.6 Buspirone